Moleculin to price IPO of 2 million shares between $5.00 and $6.00

Bonwick Capital Partners and Network 1 Financial Securities to assist

By Devika Patel

Knoxville, Tenn., Feb. 1 – Moleculin Biotech, Inc. will sell between 1.4 million and 2 million common shares in its initial public offering, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The company has registered up to $12 million of stock.

The shares will be sold at a price expected to fall between $5.00 and $6.00 per share.

Bonwick Capital Partners LLC is the representative of the underwriters and, with Network 1 Financial Securities, Inc., is also a co-manager.

Proceeds will be used for clinical trials, research and working capital.

The pharmaceutical company is based in Houston. The company expects its shares will trade on the Nasdaq under the symbol “MBRX.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.